Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CRISPR-Cas9 screening identifies an IRF1-SOCS1-mediated negative feedback loop that limits CXCL9 expression and antitumor immunity.
House IG, Derrick EB, Sek K, Chen AXY, Li J, Lai J, Todd KL, Munoz I, Michie J, Chan CW, Huang YK, Chan JD, Petley EV, Tong J, Nguyen D, Engel S, Savas P, Hogg SJ, Vervoort SJ, Kearney CJ, Burr ML, Lam EYN, Gilan O, Bedoui S, Johnstone RW, Dawson MA, Loi S, Darcy PK, Beavis PA. House IG, et al. Cell Rep. 2023 Aug 29;42(8):113014. doi: 10.1016/j.celrep.2023.113014. Epub 2023 Aug 21. Cell Rep. 2023. PMID: 37605534 Free article.
Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3- Cell-Mediated Modulation of CD103+ Dendritic Cells.
Beavis PA, Henderson MA, Giuffrida L, Davenport AJ, Petley EV, House IG, Lai J, Sek K, Milenkovski N, John LB, Mardiana S, Slaney CY, Trapani JA, Loi S, Kershaw MH, Haynes NM, Darcy PK. Beavis PA, et al. Among authors: house ig. Cancer Immunol Res. 2018 Sep;6(9):1069-1081. doi: 10.1158/2326-6066.CIR-18-0291. Epub 2018 Jul 17. Cancer Immunol Res. 2018. PMID: 30018045
Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, Todd KL, Henderson MA, Giuffrida L, Petley EV, Sek K, Mardiana S, Gide TN, Quek C, Scolyer RA, Long GV, Wilmott JS, Loi S, Darcy PK, Beavis PA. House IG, et al. Clin Cancer Res. 2020 Jan 15;26(2):487-504. doi: 10.1158/1078-0432.CCR-19-1868. Epub 2019 Oct 21. Clin Cancer Res. 2020. PMID: 31636098
Tissue-specific tumor microenvironments influence responses to immunotherapies.
Oliver AJ, Davey AS, Keam SP, Mardiana S, Chan JD, von Scheidt B, Beavis PA, House IG, Van Audernaerde JR, Darcy PK, Kershaw MH, Slaney CY. Oliver AJ, et al. Among authors: house ig. Clin Transl Immunology. 2019 Nov 21;8(11):e1094. doi: 10.1002/cti2.1094. eCollection 2019. Clin Transl Immunology. 2019. PMID: 31768254 Free PMC article.
Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity.
Lai J, Mardiana S, House IG, Sek K, Henderson MA, Giuffrida L, Chen AXY, Todd KL, Petley EV, Chan JD, Carrington EM, Lew AM, Solomon BJ, Trapani JA, Kedzierska K, Evrard M, Vervoort SJ, Waithman J, Darcy PK, Beavis PA. Lai J, et al. Among authors: house ig. Nat Immunol. 2020 Aug;21(8):914-926. doi: 10.1038/s41590-020-0676-7. Epub 2020 May 18. Nat Immunol. 2020. PMID: 32424363
23 results